Compare Starbucks Corp (SBUX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Starbucks Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Starbucks Corp trades at $90.75 (market cap $106.26B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Starbucks Corp is far larger — about 10.5× State Street SPDR S&P Biotech ETF's market cap, and Starbucks Corp pays a 2.7% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Starbucks Corp for 190 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| SBUX | XBI | |
|---|---|---|
Market Cap | $106.26B | $10.11B |
Volume | 30,248,434 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $108.55 | $169.55 |
52-Week Low | $78.46 | $104.99 |
Typical Hold Time | 190 Days | 38 Days |
Enterprise Value | $125.08B | — |
Dividend Yield | 2.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Starbucks (SBUX) trades at $93.21, down 0.4% with bearish technical signals. Recent earnings show mixed results with Q2 2026 beating expectations but Q4 2025 missing. The company is undergoing strategic restructuring with 250 store closures announced in September 2026, while maintaining dividend payments. Revenue growth remains modest at $37.18B for 2025 with net income margin at 5.17%. Analyst consensus remains positive with a $115.50 price target despite current bearish technical indicators.
SBUX presents a turnaround opportunity with strong analyst support but faces execution risks from store closures and competitive pressures. The stock trades at premium valuations (P/E 53.88) requiring sustained earnings growth. Near-term volatility expected during restructuring, while long-term prospects depend on successful portfolio optimization and international expansion, particularly in Asian markets.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
